目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T8372 | Potassium Channel | ||
VU 0134992 是一个亚型偏好的,口服有效的和选择性的内向整流钾通道 Kir4.1阻滞剂,IC50为 0.97 μM。在 -120 mV 时,VU0134992对同分 Kir4.1 比 Kir4.1/5.1 共分通道 (IC50=9 μM) 高出 9 倍的选择性。 | |||
T13316 | Potassium Channel | ||
VU0134992 hydrochloride 是一个亚型偏好的,具有口服活性和选择性的内向整流钾通道Kir4.1阻滞剂,IC50为 0.97 μM。在 -120 mV 时,VU0134992 hydrochloride 对同分 Kir4.1 比 Kir4.1/5.1 共分通道 (IC50=9 μM) 高出 9 倍的选择性。 | |||
T1484L | Apoptosis RAAS MRP | ||
Perindopril erbumine (S9490-3) 是一种长效血管紧张素转换酶抑制剂。 | |||
T1083L | HDAC PDE Adenosine Receptor | ||
Theophylline monohydrate (Quibron) 似乎抑制磷酸二酯酶和前列腺素的产生,调节钙通量和细胞内钙分布,并拮抗腺苷。茶碱是黄嘌呤的天然生物碱衍生物,从植物山茶花和小粒咖啡中分离出来。在生理上,该药剂可放松支气管平滑肌,产生血管舒张(脑血管除外),刺激中枢神经系统,刺激心肌,利尿,增加胃酸分泌;它还可以抑制炎症并改善横膈膜的收缩性。 | |||
T1400L | Antibacterial | ||
Demeclocycline (Declostatin) 是一种四环素类抗生素,产自金霉素链霉菌(Streptomyces aureofaciens)菌株。Demeclocycline 具有抗菌活性,能抑制血管加压素对肾小管的作用,从而导致利尿。Demeclocycline 可用诱导尿崩症和急性肾衰竭。 | |||
T28313 | |||
PD 117302 is a nonpeptide opioid compound. It is a selective kappa-opioid agonist. PD 117302 causes naloxone-reversible locomotor impairment and diuresis. It is an Anti-Arrhythmia Agent, an Anticonvulsants, a Cardiovascular Agent, and a Central Nervous Sy | |||
T70939 | |||
8-Aminoinosine is an endogenous 8-aminopurine that induces diuresis, natriuresis, and glucosuria by inhibiting purine nucleoside phosphorylase (PNPase). | |||
T73218 | |||
Epitizide 是一种苯并噻二嗪,常与Triamterene 联合使用,产生利尿作用。 | |||
T70250 | |||
Demeclocycline calcium is a semisynthetic tetracycline antibiotic which was derived from a strain of Streptomyces aureofaciens. Demeclocycline binds to bacterial 30S ribosomal subunit and prevents binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Demeclocycline also inhibits the effect of vasopressin on the renal tubules, thereby causing diuresis. | |||
TP1209 | |||
Acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body\'s sa |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00875 | NPPB Protein, Human, Recombinant (His) | Human | E. coli | ||
Human Natriuretic peptides B acts as a cardiac hormone; it is associated with many biological actions, such as diuresis, natriuresis, vasorelaxation, which inhibits the secretion of rennin and aldosterone. It acts as a paracrine antifibrotic factor in the heart. Natriuretic peptides B can help restore the body balance of salt and water, improves the heart function. Natriuretic peptides B binds and stimulates the cGMP production of the NPR1 receptor and binds the clearance receptor NPR3.
|
|||||
TMPH-03250 | NPR3 Protein, Rat, Recombinant (His & SUMO) | Rat | E. coli | ||
Receptor for the natriuretic peptide hormones, binding with similar affinities atrial natriuretic peptide NPPA/ANP, brain natriuretic peptide NPPB/BNP, and C-type natriuretic peptide NPPC/CNP. May function as a clearance receptor for NPPA, NPPB and NPPC, regulating their local concentrations and effects. May regulate diuresis, blood pressure and skeletal development. Does not have guanylate cyclase activity.
|
|||||
TMPJ-00734 | KNG1 Protein, Human, Recombinant (His) | Human | Human Cells | ||
Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn’t involved in blood clotting.
|